Sphincter-Preserving Therapy for Treating a Chronic Anal Fissure: Long-term Outcomes

Ridzuan Farouk

doi:10.3393/ac.2014.30.3.132

Articles

Page Path: HOME > Ann Coloproctol > Volume 30(3); 2014 > Article

Original Article Sphincter-Preserving Therapy for Treating a Chronic Anal Fissure: Long-term Outcomes: Ridzuan Farouk; Annals of Coloproctology 2014;30(3):132-134.
DOI: https://doi.org/10.3393/ac.2014.30.3.132
Published online: June 23, 2014

Department of Surgery, National University Hospital, Singapore.

Correspondence to: Ridzuan Farouk, LLB (Hons) MCh FRCS. Department of Surgery, National University Hospital, Tower Block #8, 1E Kent Ridge Road, Singapore 119228, Singapore. Tel: +65-6772-4235, Fax: +65-6777-8206, ridzuan_farouk@nuhs.edu.sg

• Received: September 3, 2013 • Accepted: November 24, 2013

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next

7,042 Views
65 Download
15 Web of Science
13 Crossref
17 Scopus

Full Article

Download PDF

Abstract
INTRODUCTION
METHODS
RESULTS
DISCUSSION
ARTICLE INFORMATION
REFERENCES

Abstract

Purpose
To estimate the risk of recurrent fissure in ano after sphincter preserving treatments.
Methods
A retrospective case note review, combined with a telephone survey was conducted for all patients treated for a chronic anal fissure between 1998 and 2008.
Results
Six hundred and twelve patients (303 women: mean age, 39 years; range, 16-86 years) were treated for chronic anal fissure between 1998 and 2008. Topical diltiazem 2% was initially prescribed for 8 weeks. The fissure did not heal in 141 patients. These patients (61 women: mean age, 30 years; range, 15-86 years) were treated with 100 IU botulinum A toxin (Botox) injection combined with a fissurectomy under general anaesthesia. Thirty eight patients suffered a recurrence of their fissure within two years. Thirty-four healed with further medical or sphincter conserving surgical therapy while four required a lateral internal sphincterotomy.
Conclusion
The vast majority of patients with chronic anal fissure can be treated with sphincter conserving treatments. This may require several interventions before healing can be achieved. Assessment for recurrence after 'conservative' treatments requires a minimum of two-year follow-up.
Keywords: Fissure in ano

INTRODUCTION

A reversible chemical sphincterotomy using topical glyceryl trinitrate (GTN) was described as a potential medical therapy for chronic anal fissure in 1991 [1]. Application of GTN is associated with a significant reduction in resting anal pressure and a reduction in pain scores [2]. Long-term healing can be achieved in 59% of patients treated in this way [2]. Significant side-effects of headache and poor fissure healing rates have discouraged some from using a chemical sphincterotomy as a treatment option for chronic anal fissure [3]. A lateral sphincterotomy results in superior healing rates [4] and remains the gold standard treatment for chronic anal fissure [5]. The risk of incontinence after a lateral sphincterotomy is small [5], but its role in treating women with a significant obstetric history, older patients, and those who have undergone previous anal surgery has spurred the development of alternative sphincter-sparing treatments for patients with chronic anal fissure.

Anal advancement flaps [6] and botulinum A toxin (Botox) injection combined with a fissurectomy [7] represent alternative surgical approaches that preserve anal sphincter integrity. The significant side-effect profile of GTN has resulted in alternative pharmacological forms of a chemical sphincterotomy including Botox injection and topical diltiazem application [8, 9]. This paper reports our experience with sphincter-preserving treatments in consecutive patients presenting with chronic anal fissure. Long-term outcomes are reported along with the details of any salvage treatments delivered.

METHODS

Chronic anal fissure is defined as a visible split in the midline of the anoderm with symptoms of anal pain and/or bleeding present for a minimum of six weeks. Patients with Crohn's disease, radiation proctitis or slow transit constipation were excluded from the study.

All patients were treated with topical diltiazem 2% ointment applied twice daily for eight weeks. Additional treatment with a high-fiber diet and a stool softener was encouraged in patients who did not suffer from diarrhea. Patients whose fissure had healed were discharged with advice to continue with a high-fiber diet and a stool softener for a minimum of three months. Those with a persistent fissure were prescribed with a second course of diltiazem for an additional eight weeks. A persistent fissure despite sixteen weeks of topical diltiazem resulted in a fissurectomy and injection of 100 IU of botulinum A toxin (Botox). Patients whose fissure did not heal after a fissurectomy and Botox injection were offered a choice of GTN ointment, a second Botox injection with fissurectomy, an anal advancement flap, or lateral sphincterotomy.

Late patient outcomes were determined by telephone interviews two and five years after surgery. When patients could not be contacted, their family doctors were contacted and their hospital records were checked to determine whether any additional treatments had later become necessary. These processes were repeated again in 2007, 2010, and 2013 to ensure completeness of data collection.

RESULTS

Between 1998 and 2008, 612 patients (303 women and 309 men) were treated for a chronic anal fissure by using topical diltiazem 2% ointment four hospitals (Royal Berkshire Hospital, West Berkshire Community Hospital, Dunedin Hospital, and Berkshire Independent Hospital, Reading, UK). The median age of the patients treated was 39 years (range, 15-86 years). Thirty patients (5%) developed a contact dermatitis as a result of using the cream, and ninety-two patients (15%) complained of pruritus ani during or shortly after completion of their treatment.

One hundred forty-one patients (23%) either did not heal with topical diltiazem ointment or relapsed after stopping treatment. The median age of these patients was 30 years (range, 16-86 years). All underwent a fissurectomy and had 100-IU Botox injected, divided in 50-IU aliquots, into the intersphincteric space at the three and nine o'clock positions with the patient in the lithotomy position under general anesthesia. Eleven patients (8%) reported transient urgency for defecation lasting up to twelve weeks after this procedure.

Thirty-eight of these one hundred and forty-one patients (26%) did not heal immediately after their fissurectomy & Botox procedure (12 patients) or suffered a recurrence within two years of their surgery (25 patients). Nine healed with topical GTN cream, 20 underwent a second fissurectomy and Botox injection, five were treated with an anal advancement flap and four patients underwent lateral internal sphincterotomy. Two patients did not respond to these repeat treatments and were referred elsewhere for further treatment.

One patient who had undergone a lateral internal sphincterotomy reported permanent fecal urgency at the two- and the five-year follow-ups.

DISCUSSION

The majority of patients presenting with chronic anal fissure have evidence of reduced anodermal blood flow [10], high resting anal pressure [2, 11] and ultraslow waves [11] suggestive of internal anal sphincter spasms. Lateral internal sphincterotomy represents the gold standard of treatment [5] against which new treatments should be compared. Early recurrence after sphincter-conserving therapy is common, and this research would suggest that a minimum of two-year follow-up is required to determine the efficacy of alternative treatments.

Endoanal ultrasound combined with anal manometry has established a cohort of patients with an anal fissure at increased risk of fecal incontinence following a lateral sphincterotomy. These include women with an obstetric history [12], patients who have undergone previous anal surgical procedures [13, 14], and older patients with a short anal sphincter [15].

Topical diltiazem 2% ointment was used as it appears to be at least equally efficacious as GTN but with fewer side-effects. A high-fiber diet and the use of a stool softener during treatment and for a period afterwards has in all likelihood contributed to improved healing rates and minimized long-term recurrence. The primary side-effects of diltiazem 2% ointment appear to be perianal dermatitis and pruritus ani.

Failure of treatment with topical diltiazem resulted in a fissurectomy and Botox injection. The fissurectomy, performed with a curette, converts the chronic fissure into an acute wound. The mechanism of action of the Botox injection remains unclear, but it may improve anodermal blood flow either by chemical relaxation of the anal sphincter and/or vasodilation.

The dose of Botox used in this study is higher than that published in earlier series but has not translated into high rates of fecal incontinence. The 100 units are diluted into 2 mL. of saline allowing 50 IU aliquots of Botox to be injected into the intersphincteric space. Whether there is any advantage of this injection site over others remains to be resolved but the 3 and 9 o'clock positions using an anal speculum to demonstrate the intersphincteric space is surgically convenient. The ideal dose of Botox required is also unresolved with previous reports varying the amount of Botox used varying between 12 and 50 IU per injection.

Initial success after treatment of an anal fissure, as measured by resolution of pain and healing of the fissure, is tempered by recurrent symptoms, and treatment efficacy should only be judged with adequate follow-up. Twenty-five of our patients who initially responded to their Botox injection and fissurectomy relapsed at a later time. A minimum two-year follow-up appears necessary to adequately determine treatment success.

A second cycle of topical cream or a fissurectomy & Botox injection can sometimes avoid a subsequent sphincterotomy. Patient motivation, counseling of risks involved with treatment options available, and the ability to deliver a package of treatment options, including undertaking an anal advancement flaps, determine which steps are available to minimize the need for sphincter division, thereby keeping the risks of incontinence to a minimum [16].

In conclusion, conservative therapy for a chronic anal fissure includes medical and surgical techniques. A stepwise approach to treatment that incorporates medical and surgical treatments is time consuming and requires patient counseling, but ultimately such an approach can successfully preserve the integrity of the anal sphincter muscle for the majority of patients. Recurrences are common, so long-term follow-ups of patients who underwent conservative therapies are required to fully assess the efficacy of treatment.

ARTICLE INFORMATION

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Loder PB, Kamm MA, Nicholls RJ, Phillips RK. 'Reversible chemical sphincterotomy' by local application of glyceryl trinitrate. Br J Surg 1994;81:1386–1389. Article PubMed
2. Kennedy ML, Sowter S, Nguyen H, Lubowski DZ. Glyceryl trinitrate ointment for the treatment of chronic anal fissure: results of a placebo-controlled trial and long-term follow-up. Dis Colon Rectum 1999;42:1000–1006. Article PubMed
3. Altomare DF, Rinaldi M, Milito G, Arcana F, Spinelli F, Nardelli N, et al. Glyceryl trinitrate for chronic anal fissure--healing or headache? Results of a multicenter, randomized, placebo-controled, double-blind trial. Dis Colon Rectum 2000;43:174–179. Article PubMed
4. Libertiny G, Knight JS, Farouk R. Randomised trial of topical 0.2% glyceryl trinitrate and lateral internal sphincterotomy for the treatment of patients with chronic anal fissure: long-term follow-up. Eur J Surg 2002;168:418–421. Article PubMed
5. Nelson RL. Operative procedures for fissure in ano. Cochrane Database Syst Rev 2010;(1): CD002199.Article PubMed
6. Nyam DC, Wilson RG, Stewart KJ, Farouk R, Bartolo DC. Island advancement flaps in the management of anal fissures. Br J Surg 1995;82:326–328. Article PubMed
7. Scholz T, Hetzer FH, Dindo D, Demartines N, Clavien PA, Hahnloser D. Long-term follow-up after combined fissurectomy and Botox injection for chronic anal fissures. Int J Colorectal Dis 2007;22:1077–1081. Article PubMed
8. Knight JS, Birks M, Farouk R. Topical diltiazem ointment in the treatment of chronic anal fissure. Br J Surg 2001;88:553–556. Article PubMed
9. Samim M, Twigt B, Stoker L, Pronk A. Topical diltiazem cream versus botulinum toxin a for the treatment of chronic anal fissure: a double-blind randomized clinical trial. Ann Surg 2012;255:18–22. Article PubMed
10. Schouten WR, Briel JW, Auwerda JJ, De Graaf EJ. Ischaemic nature of anal fissure. Br J Surg 1996;83:63–65. Article PubMed
11. Farouk R, Duthie GS, MacGregor AB, Bartolo DC. Sustained internal sphincter hypertonia in patients with chronic anal fissure. Dis Colon Rectum 1994;37:424–429. Article PubMed
12. Corby H, Donnelly VS, O'Herlihy C, O'Connell PR. Anal canal pressures are low in women with postpartum anal fissure. Br J Surg 1997;84:86–88. Article PubMed
13. Farouk R, Bartolo DC. The use of endoluminal ultrasound in the assessment of patients with faecal incontinence. J R Coll Surg Edinb 1994;39:312–318. PubMed
14. Tjandra JJ, Han WR, Ooi BS, Nagesh A, Thorne M. Faecal incontinence after lateral internal sphincterotomy is often associated with coexisting occult sphincter defects: a study using endoanal ultrasonography. ANZ J Surg 2001;71:598–602. Article PubMed
15. Frudinger A, Halligan S, Bartram CI, Price AB, Kamm MA, Winter R. Female anal sphincter: age-related differences in asymptomatic volunteers with high-frequency endoanal US. Radiology 2002;224:417–423. Article PubMed
16. Hancke E, Rikas E, Suchan K, Volke K. Dermal flap coverage for chronic anal fissure: lower incidence of anal incontinence compared to lateral internal sphincterotomy after long-term follow-up. Dis Colon Rectum 2010;53:1563–1568. Article PubMed

Figure & Data

References

Citations

Citations to this article as recorded by

Effectiveness of combined botulinum toxin and fissurectomy on chronic anal fissures – a systematic review
Rakesh Quinn, Giuleta Jamsari, Gary KK Low, Sinan Albayati
ANZ Journal of Surgery.2025; 95(3): 293. CrossRef
Study on duration of symptoms of anal fissure and its impact on response to conservative treatment – A systemic review
Kamal Raut
Journal of Preventive Medicine and Holistic Health.2024; 10(2): 43. CrossRef
The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Anal Fissures
Jennifer S. Davids, Alexander T. Hawkins, Anuradha R. Bhama, Adina E. Feinberg, Michael J. Grieco, Amy L. Lightner, Daniel L. Feingold, Ian M. Paquette
Diseases of the Colon & Rectum.2023; 66(2): 190. CrossRef
Fisurectomy and anoplasty with botulinum toxin injection in patients with chronic anal posterior fissure with hypertonia: a long-term evaluation
Beatrice D’Orazio, Girolamo Geraci, Guido Martorana, Carmelo Sciumé, Giovanni Corbo, Gaetano Di Vita
Updates in Surgery.2021; 73(4): 1575. CrossRef
S3-Leitlinie: Analfissur
Lukas Marti, Stefan Post, Alexander Herold, Oliver Schwandner, Franc Hetzer, Bernhard Strittmatter, Igors Iesalnieks, Marcus Huth, Martin Schmidt-Lauber, Gerhard Weyandt, Andreas Ommer, Sabrina M. Ebinger
coloproctology.2020; 42(2): 90. CrossRef
Anoplastia com plicoma sentinela para o tratamento de fissura anal crônica.
Carlos Walter Sobrado Júnior, José Américo Bacchi Hora, Lucas Faraco Sobrado, Vivian Regina Guzela, Sérgio Carlos Nahas, Ivan Cecconello
Revista do Colégio Brasileiro de Cirurgiões.2019;[Epub] CrossRef
Long‐term outcomes of Botulinum toxin in the treatment of chronic anal fissure: 5 years of follow‐up
Sandra Barbeiro, Catarina Atalaia‐Martins, Pedro Marcos, Cláudia Gonçalves, Manuela Canhoto, Bruno Arroja, Filipe Silva, Isabel Cotrim, Liliana Eliseu, Antonieta Santos, Helena Vasconcelos
United European Gastroenterology Journal.2017; 5(2): 293. CrossRef
Efficacy of nitroglycerine ointment in the treatment of pediatric anal fissure
Ali E. Joda, Ali F. Al-Mayoof
Journal of Pediatric Surgery.2017; 52(11): 1782. CrossRef
High-dose versus low-dose botulinum toxin in anal fissure disease
P. Ravindran, D. L. Chan, C. Ciampa, R. George, G. Punch, S. I. White
Techniques in Coloproctology.2017; 21(10): 803. CrossRef
Pathophysiology of fecal incontinence differs between men and women: a case‐matched study in 200 patients
D. C. Townsend, E. V. Carrington, U. Grossi, R. E. Burgell, J. Y. J. Wong, C. H. Knowles, S. M. Scott
Neurogastroenterology & Motility.2016; 28(10): 1580. CrossRef
Treatment of Gastrointestinal Sphincters Spasms with Botulinum Toxin A
Giuseppe Brisinda, Nicola Sivestrini, Giuseppe Bianco, Giorgio Maria
Toxins.2015; 7(6): 1882. CrossRef
Prospective multicenter observational trial on the safety and efficacy of LEVORAG® Emulgel in the treatment of acute and chronic anal fissure
R. Digennaro, G. Pecorella, S. La Manna, A. Alderisio, A. Alderisio, B. De Pascalis, D. Pennisi, G. Santangelo, F. Pezzolla, A. Racalbuto, G. Serra, A. Pulvirenti D’Urso, D. F. Altomare
Techniques in Coloproctology.2015; 19(5): 287. CrossRef
Treatment Option for Aged, Multiparous Women With a Chronic Anal Fissure
Yong Hee Hwang
Annals of Coloproctology.2014; 30(3): 106. CrossRef

Cite this Article

Cite this Article: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Sphincter-Preserving Therapy for Treating a Chronic Anal Fissure: Long-term Outcomes

Ann Coloproctol. 2014;30(3):132-134. Published online June 23, 2014

DOI: https://doi.org/10.3393/ac.2014.30.3.132

XML Download

Sphincter-Preserving Therapy for Treating a Chronic Anal Fissure: Long-term Outcomes